2-Apr-2026
Business Wire (Fri, 3-Apr 5:50 PM ET)
Most and least shorted mid-to mega-cap healthcare stocks in March
Seeking Alpha News (Fri, 3-Apr 8:00 AM ET)
Globe Newswire (Wed, 1-Apr 2:07 PM ET)
Novo to sell Wegovy subscriptions on Hims, LifeMD, and others
Seeking Alpha News (Tue, 31-Mar 8:07 AM ET)
Tango Therapeutics is the best performing healthcare stock in March
Seeking Alpha News (Mon, 30-Mar 2:10 PM ET)
Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers
Business Wire (Thu, 26-Mar 12:00 PM ET)
Market Chameleon (Wed, 11-Mar 7:15 AM ET)
3 Reasons Why this HIMS Credit Put Spread Could be a Good Trade at $0.64
Market Chameleon (Wed, 11-Mar 10:18 AM ET)
Hims & Hers Names Kathryn Beiser as Chief Communications Officer
Business Wire (Tue, 10-Mar 8:08 PM ET)
Market Chameleon (Tue, 10-Mar 6:37 AM ET)
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of April 2, 2026, HIMS stock price declined to $19.14 with 22,130,900 million shares trading.
HIMS has a beta of 1.25, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.04 to the broad based SPY ETF.
HIMS has a market cap of $4.36 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $618 million in Revenue and $.08 earnings per share. This fell short of revenue expectation by $-207,922 and exceeded earnings estimates by $.05.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): IJH, IWM, VTI, VB, VBK.
HIMS has underperformed the market in the last year with a price return of -38.7% while the SPY ETF gained +17.5%. HIMS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.7% and -20.8%, respectively, while the SPY returned -3.7% and -0.1%, respectively.
HIMS support price is $18.41 and resistance is $21.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.